← Peptide library
Peptide comparison
This page compares Sermorelin and Ipamorelin side by side, drawing on the published reference data for each compound. Neither has an established subcutaneous dose. Sermorelin’s former U.S. products were discontinued, and Ipamorelin’s only published human dosing figure is intravenous, from a trial that did not meet its primary endpoint. The points below lay out how each compound is characterized in its own cited source.
Sermorelin
Ipamorelin
Former U.S. Geref products discontinued; no current FDA-approved indication
Investigational/discontinued; not FDA-approved
Historical approval / published human studies
Published Phase 2 human RCT; negative primary endpoint
Subcutaneous historically
Intravenous in cited trial
No current established regimen
Twice daily (IV study)
No established range
0.03 mg/kg (intravenous)
Sermorelin vs Ipamorelin: at a glance
| Attribute | Sermorelin | Ipamorelin |
|---|---|---|
| Regulatory status | Former U.S. Geref products discontinued; no current FDA-approved anti-aging indication | Investigational/discontinued; not FDA-approved |
| Route | Subcutaneous historically | Intravenous in cited trial |
| Dosing frequency | No current established regimen | Twice daily (IV study) |
| Published range | No established range | 0.03 mg/kg |
| Evidence basis | Historical approval / published human studies | Published Phase 2 human RCT; negative primary endpoint |
| What the source describes | Historical pediatric and adult studies used weight-based regimens; no current FDA-approved adult 'wellness' dose | Postoperative ileus trial used 0.03 mg/kg IV twice daily up to 7 days; primary endpoint not met |
| Formulation | No default dose. Follow the exact current prescriber/pharmacy instructions if a lawful compounded product is used. | Do not use the IV study value as a subcutaneous protocol. No established outpatient injectable dose. |
Every value is quoted from each compound's own labeling or published trial, listed in the sources below. A published range describes what has been studied or labeled - it is not a recommendation, and this page does not advise choosing one compound over the other. There is no valid dose conversion between two different compounds.
What is not established
| Compound | Established dose range | Stated limitation |
|---|---|---|
| Sermorelin | None established | Historical approval does not validate current compounded formulations or adult anti-aging use. |
| Ipamorelin | 0.03 mg/kg | FDA notes immunogenicity/impurity concerns and serious adverse events including death in IV study context. |
Sources
| Compound | Primary source | Checked |
|---|---|---|
| Sermorelin | FDA archived new drug application document (Sermorelin) - accessdata.fda.gov | 2026-06-24 |
| Ipamorelin | PubMed - PMID 25331030 | 2026-06-24 |
Key differences
Neither compound has a current approved indication. Sermorelin was approved in the United States as Geref and those products were discontinued, so the historical approval does not validate present-day compounded use. Ipamorelin was investigational and is likewise not approved. The sharpest difference is in the evidence: Sermorelin’s figures come from studies conducted under its former approval, while Ipamorelin’s single published human dosing figure comes from an intravenous postoperative-ileus trial that did not meet its primary endpoint. Because that figure is intravenous, it does not transfer to subcutaneous use, and neither compound has an established outpatient injectable dose.
Reference comparison only. Not medical advice; verify with a clinician, product label, pharmacist, or approved research protocol.
Frequently asked questions
How are Sermorelin and Ipamorelin administered in the cited sources?
They differ, and the difference matters. The Sermorelin figures come from its historical U.S. labeling and the studies conducted under it, where it was given subcutaneously. The Ipamorelin figure comes from an intravenous clinical trial. An intravenous study dose does not transfer to subcutaneous use, so the two columns are not directly comparable.
What dose figures does this comparison reference?
Only what the cited sources state. Sermorelin has no current established range: its former U.S. products were discontinued and no current approved adult dose exists. Ipamorelin has a single published figure, 0.03 mg/kg given intravenously twice daily in the cited trial, which did not meet its primary endpoint. Neither figure is a recommendation.
Can I calculate reconstitution for both here?
Yes. Open either compound’s calculator from the buttons above to convert your own inputs into concentration (mg/mL), draw volume and U-100 syringe units. The calculators do arithmetic on figures you enter. Neither carries a preset dose, because neither compound has an established one.
Does this page recommend one over the other?
No. Neither compound has a current approved indication and neither has an established subcutaneous dose. This page is a neutral reference and does not assess efficacy, safety, or suitability. Those decisions belong with a qualified clinician.